Listed

Xtant Medical Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 14, 2018 and accepted by EDGAR at Nov 14, 2018, 17:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue3 months2018-07-01 to 2018-09-30$5.7mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2018-01-01 to 2018-09-30$17.7mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-07-01 to 2018-09-30$11.5mus-gaap:GrossProfit
Gross profit9 months2018-01-01 to 2018-09-30$36.2mus-gaap:GrossProfit
Research and development3 months2018-07-01 to 2018-09-30$347.0kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$1.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-07-01 to 2018-09-30−$1.4mus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30−$5.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2018-07-01 to 2018-09-30$1.8mus-gaap:InterestExpense
Interest expense9 months2018-01-01 to 2018-09-30$8.2mus-gaap:InterestExpense
Net income3 months2018-07-01 to 2018-09-30−$3.2mus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30−$13.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30−$0.24us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30−$1.19us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-07-01 to 2018-09-30−$0.24us-gaap:EarningsPerShareBasic
Basic EPS9 months2018-01-01 to 2018-09-30−$1.19us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2018-07-01 to 2018-09-3013,158,326 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2018-01-01 to 2018-09-3011,262,642 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2018-01-01 to 2018-09-30−$779.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-01-01 to 2018-09-30$308.0kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2018-09-30$5.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$37.9mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$99.3mus-gaap:Assets
Current liabilitiesAt period end2018-09-30$10.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-30$86.6mus-gaap:Liabilities
Long-term debtAt period end2018-09-30$75.9mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2018-09-30$12.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-18-016195. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.